Table 1 Characteristics of included studies in the meta-analysis
Autor | Year | Country | Disease | Procedure | No. of participants | Outcomes | Study design | ||
|---|---|---|---|---|---|---|---|---|---|
no-ENBD | ENBD | Primary | Secondary | ||||||
Huang | 2018 | China | Choledocholithiasis | ERCP + EPBD + EST | 77 | 78 | PEP | Hyperamylasemia | RCT |
Lee | 2010 | Korea | Choledocholithiasis-induced acute cholangitis | ERCP + EST | 53 | 51 | Cholangitis; PHD | Operation time; Patient discomfort on day 1 after the procedure; Normalization time of TB and AST; Remnant CBD stones; Complication | RCT |
Xu | 2015 | China | Choledocholithiasis | ERCP + EPBD ERCP + EST ERCP | 105 | 113 | Normalization time of TB, ALT and CRP; PHD; Complications; OPC | RCT | |
Yang | 2013 | China | Choledocholithiasis | ERCP + EST | 89 | 99 | Complications; Normalization time of TB; PHD | Cohort study | |
Yang | 2020 | China | Choledocholithiasis | LC + LCBDE + PC | 81 | 83 | Closure methods; Suture materials; Operation time; Intraoperative bleeding; Postoperative first flatus; Abdominal drainage time; Postoperative antibiotic therapy; PHD; Cost; Complications | Cohort study | |
Zhang | 2023 | China | cholecystolithiasis combined with choledocholithiasis | LC + LCBDE + PC | 72 | 96 | Operation time; Intraoperative bleeding; PHD; Cost; Abdominal drainage time; Complications; The stone clearance and recurrence rates | Cohort study | |